Cerulean’s siRNA-containing nanopharmaceuticals are taken up into tumor cells expressing green fluorescent protein (GFP), where they release their payload and decrease the expression of GFP. Nanopharmaceuticals are shown in red and green intensity correlates with the level of GFP expression.
Cerulean’s clinically validated nanopharmaceutical platform allows us to:
- Develop our own small molecule oncology products
- Potentially solve class limiting problems such as delivery of siRNA and peptides
- Develop products with partners by marrying their molecules, marketed or in development, with our platform
Learn more about CRLX101
Learn more about CRLX301
Learn more about Cerulean’s RNA Delivery Program